| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Beacon Health is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Medicus Firm is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CRH Medical Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gateway Healthcare (GHI) is a non-profit behavioral health care organization that provides a wide array of services to adults, children and families in Rhode Island. We provide services to people of all cultural and economic backgrounds, who may not